Literature DB >> 19390506

Malignant mesothelioma mortality--United States, 1999-2005.

.   

Abstract

Malignant mesothelioma is a fatal cancer primarily associated with exposure to asbestos. The latency period between first exposure to asbestos and clinical disease usually is 20--40 years. Although asbestos is no longer mined in the United States, the mineral is still imported, and a substantial amount of asbestos remaining in buildings eventually will be removed, either during remediation or demolition. Currently, an estimated 1.3 million construction and general industry workers potentially are being exposed to asbestos. To characterize mortality attributed to mesothelioma, CDC's National Institute for Occupational Safety and Health (NIOSH) analyzed annual multiple-cause-of-death records for 1999--2005, the most recent years for which complete data are available. For those years, a total of 18,068 deaths of persons with malignant mesothelioma were reported, increasing from 2,482 deaths in 1999 to 2,704 in 2005, but the annual death rate was stable (14.1 per million in 1999 and 14.0 in 2005). Maintenance, renovation, or demolition activities that might disturb asbestos should be performed with precautions that sufficiently prevent exposures for workers and the public. In addition, physicians should document the occupational history of all suspected and confirmed mesothelioma cases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19390506

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  11 in total

1.  Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.

Authors:  Vanya Delgermaa; Ken Takahashi; Eun-Kee Park; Giang Vinh Le; Toshiyuki Hara; Tom Sorahan
Journal:  Bull World Health Organ       Date:  2011-06-13       Impact factor: 9.408

Review 2.  Local and systemic therapies for malignant pleural mesothelioma.

Authors:  Daniel Gomez; Anne S Tsao
Journal:  Curr Treat Options Oncol       Date:  2014-12

Review 3.  Environmental asbestos exposure and risk of mesothelioma.

Authors:  Curtis W Noonan
Journal:  Ann Transl Med       Date:  2017-06

4.  Accounting for outcome misclassification in estimates of the effect of occupational asbestos exposure on lung cancer death.

Authors:  Jessie K Edwards; Stephen R Cole; Haitao Chu; Andrew F Olshan; David B Richardson
Journal:  Am J Epidemiol       Date:  2013-12-18       Impact factor: 4.897

Review 5.  Lung cancer: epidemiology, etiology, and prevention.

Authors:  Charles S Dela Cruz; Lynn T Tanoue; Richard A Matthay
Journal:  Clin Chest Med       Date:  2011-12       Impact factor: 2.878

Review 6.  [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas].

Authors:  Volker Neumann; Stefan Löseke; Andrea Tannapfel
Journal:  Med Klin (Munich)       Date:  2009-10-25

7.  Global magnitude of reported and unreported mesothelioma.

Authors:  Eun-Kee Park; Ken Takahashi; Tsutomu Hoshuyama; Tsun-Jen Cheng; Vanya Delgermaa; Giang Vinh Le; Tom Sorahan
Journal:  Environ Health Perspect       Date:  2011-04       Impact factor: 9.031

8.  Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma--a pilot study.

Authors:  Daniel G Weber; Georg Johnen; Oleksandr Bryk; Karl-Heinz Jöckel; Thomas Brüning
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

9.  Intrapleural Adenoviral-mediated Endothelial Cell Protein C Receptor Gene Transfer Suppresses the Progression of Malignant Pleural Mesothelioma in a Mouse Model.

Authors:  Shiva Keshava; L Vijaya Mohan Rao; Usha R Pendurthi
Journal:  Sci Rep       Date:  2016-11-11       Impact factor: 4.379

10.  Cancer prevention and worksite health promotion: time to join forces.

Authors:  Pamela Allweiss; David R Brown; L Casey Chosewood; Joan M Dorn; Shanta Dube; Randy Elder; Dawn M Holman; Heidi L Hudson; C Dexter Kimsey; Jason E Lang; Tina J Lankford; Chunyu Li; Lisa Muirhead; Antonio Neri; Marcus Plescia; Juan Rodriguez; Anita L Schill; Meredith Shoemaker; Glorian Sorensen; Julie Townsend; Mary C White
Journal:  Prev Chronic Dis       Date:  2014-07-24       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.